IPN01195
/ Ipsen, University of Montreal, IRICoR
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
July 24, 2025
Phase I/II first-in-human (FIH) study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and antitumour activity of IPN01195 as single agent in adult participants with advanced solid tumours
(ESMO 2025)
- P1/2 | "Legal entity responsible for the study Ipsen. Funding Ipsen."
Clinical • First-in-human • IO biomarker • Metastases • P1/2 data • PK/PD data • Oncology • Solid Tumor
July 08, 2025
The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and IRICoR Announce initiation of Phase 1 Trial of Licensed Small Molecule Therapy for Solid Tumors
(Canada Newswire)
- "IRIC and IRICoR today announced the start of a Phase 1 clinical trial of its small molecule therapy for solid tumors licensed to Ipsen. This marks a major milestone in the strategic collaboration between the partners, which began in May 2020 with a research and option agreement followed by a licensing agreement in February 2023. The small molecule clinical candidate, now known as IPN01195, is a RAF inhibitor, an important target in a signaling pathway involved in cancer cell growth and proliferation."
Trial status • Solid Tumor
April 19, 2025
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
(GlobeNewswire)
- "The regulatory filing for tovorafenib was accepted by EMA for review in the European Union, marking an important step forward in the development of this potential treatment for pediatric low-grade glioma and reinforcing Ipsen’s commitment to innovation in rare and difficult-to-treat cancers; Ipsen also initiated the entry in Phase I of IPN01195, a RAF inhibitor, complementing IPN01194, an ERK inhibitor, and tovorafenib, two other assets targeting the MAPK pathway."
EMA filing • Trial status • Glioma • Solid Tumor
1 to 3
Of
3
Go to page
1